Table 2.
Variables selected by the LR model (P < 0.1)
| Variable | Grouping | Coefficient | OR | P-value |
|---|---|---|---|---|
| Sex | Male | Reference | Reference | Reference |
| Female | −0.466 | 0.628 | 0.037 | |
| Stage | I | Reference | Reference | Reference |
| II | 0.744 | 2.105 | 0.161 | |
| III | 1.573 | 4.823 | 0.006 | |
| IV | 1.429 | 4.175 | 0.011 | |
| IPI | Low | Reference | Reference | Reference |
| Low-intermediate | 0.907 | 2.478 | 0.008 | |
| High-intermediate | 0.953 | 2.594 | 0.013 | |
| High | 1.210 | 3.352 | 0.016 | |
| KPS | ≥ 80 | Reference | Reference | Reference |
| <80 | 0.734 | 2.084 | 0.014 | |
| GCB | No | Reference | Reference | Reference |
| Yes | −0.792 | 0.453 | 0.041 | |
| CD10 | Negative | Reference | Reference | Reference |
| Positive | −1.144 | 0.318 | < 0.001 | |
| Rituximab | Not use | Reference | Reference | Reference |
| Use | −0.502 | 0.605 | 0.027 |
IPI international prognostic index, KPS Karnofsky performance status, GCB germinal center B-cell-like lymphoma, CD10 is immunohistochemical indicators